


AH 6809

Cat. No.:	HY-10418		
CAS No.:	33458-93-4		
Molecular Formula:	C ₁₇ H ₁₄ O ₅		
Molecular Weight:	298.29		
Target:	Prostaglandin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (83.81 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		3.3524 mL	16.7622 mL	33.5244 mL
	5 mM		0.6705 mL	3.3524 mL	6.7049 mL
	10 mM		0.3352 mL	1.6762 mL	3.3524 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: 2.5 mg/mL (8.38 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: 2.5 mg/mL (8.38 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

AH 6809 is an antagonist of EP and DP receptor, with K_is of 1217, 1150, 1597, and 1415 nM for the cloned human EP₁, EP₂, EP₃-III, and DP receptor respectively. AH 6809 has a K_i of 350 nM for mouse EP₂ receptor^{[1][2][3]}.

In Vitro

AH 6809 (1 μM; 30 min) inhibits T. serrulatus venom (TsV)-induced and PGE₂-amplified IL-1β and cAMP production in macrophages^[4].
 AH 6809 (30-300 μM) antagonizes the anti-aggregatory activity of PGD₂ in whole blood, with an apparent pA₂ of 5.35^[5].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AH 6809 (5 mg/kg; i.p.) decreases TsV-induced mortality, PGE₂ and IL-1β production and neutrophil infiltration in the lungs

of mice^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Immunol. 2020 Jan;347:104025.
- Neurol Int. 2022, 14(1), 11-33.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Abramovitz M, et, al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. *Biochim Biophys Acta*. 2000 Jan 17;1483(2):285-93.
- [2]. Kiriya M, et, al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. *Br J Pharmacol*. 1997 Sep;122(2):217-24.
- [3]. Woodward DF, et, al. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. *Biochem Pharmacol*. 1995 Nov 9;50(10):1731-3.
- [4]. Zoccal KF, et, al. Opposing roles of LTB4 and PGE2 in regulating the inflammasome-dependent scorpion venom-induced mortality. *Nat Commun*. 2016 Feb 23;7:10760.
- [5]. Keery RJ, et, al. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. *Br J Pharmacol*. 1988 Jul;94(3):745-54.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA